Refractory Acute Lymphoblastic Leukemia

The FDA granted fast track designation to PBCAR0191, a chimeric antigen receptor T-cell therapy for treatment of advanced B-cell precursor acute lymphoblastic leukemia, according to the agent’s manufacturer.

Blinatumomab appeared to confer better outcomes than standard of care among adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, according to results of a propensity score analysis published in Cancer.

CMS has finalized its plan to increase its new technology add-on payment to 65% of the total cost of chimeric antigen T-cell therapies.